February 9Feb 9 Iambic and Takeda Pharmaceutical have formed a multi-year partnership valued at over $1.7 billion. This collaboration will leverage artificial intelligence to accelerate the design of small-molecule drugs for cancer and gastrointestinal diseases. Iambic's AI model, NeuralPLexer, will be utilised to predict drug molecule binding to proteins. View the full article
Create an account or sign in to comment